# US 8,278,059 B2 · Methods and systems of using exosomes for determining phenotypes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,059 B2
- Document ID: US8278059B2
- Status: Granted
- Kind: B2
- Application number: 13/009,393
- Filed: 2011-01-19
- Published: 2011-09-29
- Granted: 2012-10-02
- Earliest claimed: 2010-02-05
- Assignees: Caris Life Sciences Luxembourg Holdings, S.A.R.L.
- Inventors: Michael Klass; Christine Kuslich; George Poste
- Web page: https://patentgrep.com/patent/US8278059B2

## CPC

- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- C12Q 1/6811: Selection methods for production or design of target specific oligonucleotides or binding molecules
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5023: {on expression patterns}
- G01N 33/54326: {Magnetic particles}
- G01N 33/575: for cancer
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 33/57555: of the prostate
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.

## Claims

### Claim 1

A method of detecting an exosome population in a biological sample, comprising determining the presence or levels of a combination of different biomarkers of said exosome population, wherein said combination of different biomarkers comprises:
i. CD9 protein, CD63 protein, CD81 protein, or a combination thereof;
ii. one or more cell-specific protein biomarker, wherein said one or more cell-specific protein biomarker comprises PCSA; and
iii. one or more protein biomarker that is indicative of a cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the exosome population is isolated from a bodily fluid from a subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein said bodily fluid is peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, pus, sebum, vomit, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, or blastocyl cavity fluid.

### Claim 4 (depends on 1)

The method of claim 1, wherein said exosome population comprises vesicles having a diameter of about 10 nm to about 800 nm.

### Claim 5 (depends on 1)

The method of claim 1, wherein said exosome population comprises vesicles having a diameter of about 30 nm to about 200 nm.

### Claim 6 (depends on 1)

The method of claim 1, wherein said exosome population is isolated from said biological sample with size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, affinity selection, microfluidic separation or a combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cancer is prostate cancer.

### Claim 8 (depends on 1)

The method of claim 1, wherein said determining comprises measuring an expression level, presence, absence, mutation, truncation, insertion, modification, sequence variation or molecular association of said proteins from said isolated exosome population.

### Claim 9 (depends on 2)

The method of claim 2, wherein said bodily fluid is blood, urine, serum or plasma.

### Claim 10 (depends on 1)

The method of claim 1, further comprising determining an amount of exosomes, a temporal evaluation of a variation in exosome half-life, a temporal evaluation of circulating exosome half-life, a temporal evaluation of exosome metabolic half-life, or determining exosome activity.

### Claim 11 (depends on 1)

The method of claim 1, wherein said one or more cell-specific protein biomarker further comprises PSMA.

### Claim 12 (depends on 1)

The method of claim 1, wherein said determining comprises use of one or more binding agent that binds to at least one of said biomarkers.

### Claim 13 (depends on 12)

The method of claim 12, wherein said one or more binding agent comprises an antigen, DNA molecule, RNA molecule, antibody, antibody fragment, aptamer, peptoid, zDNA, peptide nucleic acid (PNA), locked nucleic acids (LNA), lectin, peptide, dendrimer or chemical compound.

### Claim 14 (depends on 1)

The method of claim 1, wherein said one or more protein biomarker further comprises B7H3 protein and/or EpCam protein.

### Claim 15 (depends on 14)

The method of claim 14, wherein said one or more cell-specific protein biomarker further comprises PSMA.

### Claim 16 (depends on 7)

The method of claim 7, wherein said combination of different biomarkers further comprises miR-141 RNA biomarker.

### Claim 17 (depends on 7)

The method of claim 7, wherein said combination of different biomarkers further comprises TMPRSS2-ERG RNA biomarker.

### Claim 18 (depends on 14)

The method of claim 14, wherein said combination of different biomarkers further comprises miR-141 RNA and/or TMPRSS2-ERG RNA biomarker.

### Claim 19 (depends on 16, 17, 18)

The method of claims 16, 17 or 18, wherein said RNA biomarker is assessed by quantitative PCR, nucleic acid sequencing, hybridization assay or a combination thereof.

### Claim 20 (depends on 6)

The method of claim 6, wherein the affinity selection comprises contacting said exosomes with a binding agent that is specific for a protein biomarker selected from the group consisting of CD9 protein, CD63 protein, CD81 protein, a cell-specific biomarker, a biomarker that is indicative of a cancer, and a combination thereof.

### Claim 21 (depends on 1)

The method of claim 1, further comprising determining a presence or level of one or more microRNA in said exosome population.

### Claim 22 (depends on 1)

The method of claim 1, wherein said one or more of CD9 protein, CD63 protein and CD81 protein comprises CD9 protein.

### Claim 23 (depends on 1)

The method of claim 1, wherein said exosome population comprises a heterogeneous exosome population.

### Claim 24

A method of detecting prostate cancer in a patient comprising: detecting the levels of PCSA protein and one or more of CD9, CD63 and CD81 protein in isolated exosomes obtained from said patient, wherein elevated levels of said PCSA protein and one or more of CD9, CD63 and CD81 proteins in said isolated exosomes obtained from said patient as compared to levels of PCSA protein and one or more of CD9, CD63 and CD81 proteins in isolated exosomes obtained from a subject that does not have prostate cancer indicates that said patient has prostate cancer.

### Claim 25 (depends on 24)

The method of claim 24, wherein said exosomes are isolated from said patient with size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, affinity selection, microfluidic separation or a combination thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein the affinity selection comprises contacting said exosomes with a binding agent that is specific for a protein biomarker selected from the group consisting of PCSA protein, CD9 protein, CD63 protein, CD81 protein, and a combination thereof.

### Claim 27 (depends on 26)

The method of claim 26, further comprising determining a presence or level of at least one microRNA in said isolated exosomes.

### Claim 28 (depends on 24)

The method of claim 24, wherein said one or more of CD9, CD63 and CD81 protein comprises CD9 protein.
